UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
For the quarterly period ended March 31, 2023
OR
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
For the transition period from ____ to ____
Commission File Number 001-33351
_________________________________________________
NEUROMETRIX, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 04-3308180 | ||||
| (State or other jurisdiction of | (I.R.S. Employer Identification No.) | ||||
| incorporation or organization) | |||||
| 4B Gill Street Woburn, Massachusetts | 01801 | ||||
| (Address of principal executive offices) | (Zip Code) | ||||
(781) 890-9989
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||||||
| Common Stock, $0.0001 par value per share | NURO | The Nasdaq Stock Market LLC | ||||||
| Preferred Stock Purchase Rights | ||||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
| Large accelerated filer | Accelerated filer | Non-accelerated filer | Smaller reporting company | Emerging growth company | ||||||||||||||||||||||
| ☐ | ☐ | ☒ | ☒ | ☐ | ||||||||||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 7,839,549 shares of common stock, par value $0.0001 per share, were outstanding as of May 2, 2023
.
NeuroMetrix, Inc.
Form 10-Q
Quarterly Period Ended March 31, 2023
TABLE OF CONTENTS
| Item 1. | ||||||||
| Balance Sheets as of March 31, 2023 (unaudited) and December 31, 2022 | ||||||||
| Statements of Operations (unaudited) for the Quarters Ended March 31, 2023 and 2022 | ||||||||
| Statements of Comprehensive Loss (unaudited) for the Quarters Ended March 31, 2023 and 2022 | ||||||||
| Statements of Changes in Stockholders' Equity (unaudited) for the Quarters Ended March 31, 2023 and 2022 | ||||||||
| Statements of Cash Flows (unaudited) for the Quarters Ended March 31, 2023 and 2022 | ||||||||
| Item 2. | 12 | |||||||
| Item 3. | 17 | |||||||
| Item 4. | 18 | |||||||
| Item 1. | 19 | |||||||
| Item 1A. | 19 | |||||||
| Item 2. | 19 | |||||||
| Item 3. | 19 | |||||||
| Item 4. | 19 | |||||||
| Item 5. | 19 | |||||||
| Item 6. | 20 | |||||||
| 21 | ||||||||
3
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
NeuroMetrix, Inc.
Balance Sheets
| March 31, 2023 | December 31, 2022 | ||||||||||
| (Unaudited) | |||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 2,376,619 | $ | 4,335,020 | |||||||
| Held-to-maturity securities | 8,473,905 | 16,864,707 | |||||||||
| Available-for-sale securities | 9,402,858 | — | |||||||||
| Accounts receivable, net | 576,281 | 646,771 | |||||||||
| Inventories | 1,748,115 | 1,614,987 | |||||||||
| Prepaid expenses and other current assets | 508,391 | 645,502 | |||||||||
| Total current assets | 23,086,169 | 24,106,987 | |||||||||
| Fixed assets, net | 155,397 | 165,619 | |||||||||
| Right of use asset | 342,082 | 370,609 | |||||||||
| Other long-term assets | 26,400 | 26,400 | |||||||||
| Total assets | $ | 23,610,048 | $ | 24,669,615 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 400,299 | $ | 368,082 | |||||||
| Accrued expenses and compensation | 868,265 | 589,939 | |||||||||
| Lease obligation, current | 148,391 | 148,391 | |||||||||
| Total current liabilities | 1,416,955 | 1,106,412 | |||||||||
| Lease obligation, net of current portion | 180,345 | 207,516 | |||||||||
| Total liabilities | 1,597,300 | 1,313,928 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity: | |||||||||||
| Preferred stock | — | — | |||||||||
| Convertible preferred stock | 1 | 1 | |||||||||
| Common stock, $0.0001 par value; 25,000,000 shares authorized at March 31, 2023 and December 31, 2022; 7,781,156 and 7,771,938 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 778 | 777 | |||||||||
| Additional paid-in capital | 227,100,135 | 226,934,775 | |||||||||
| Accumulated other comprehensive income | 65,874 | — | |||||||||
| Accumulated deficit | (205,154,040) | (203,579,866) | |||||||||
| Total stockholders’ equity | 22,012,748 | 23,355,687 | |||||||||
| Total liabilities and stockholders’ equity | $ | 23,610,048 | $ | 24,669,615 | |||||||
The accompanying notes are an integral part of these interim financial statements.
1
NeuroMetrix, Inc.
Statements of Operations
(Unaudited)
| Quarters Ended March 31, | |||||||||||||||||||||||
| 2023 | 2022 | ||||||||||||||||||||||
| Revenues | $ | 1,724,771 | $ | 2,302,391 | |||||||||||||||||||
| Cost of revenues | 526,372 | 508,874 | |||||||||||||||||||||
| Gross profit | 1,198,399 | 1,793,517 | |||||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 699,425 | 710,577 | |||||||||||||||||||||
| Sales and marketing | 815,872 | 858,839 | |||||||||||||||||||||
| General and administrative | 1,393,171 | 1,186,091 | |||||||||||||||||||||
| Total operating expenses | 2,908,468 | 2,755,507 | |||||||||||||||||||||
| Loss from operations | (1,710,069) | (961,990) | |||||||||||||||||||||
| Other income, net | 135,895 | 3,428 | |||||||||||||||||||||
| Net loss | $ | (1,574,174) | $ | (958,562) | |||||||||||||||||||
| Net loss per common share, basic and diluted | $ | (0.20) | $ | (0.14) | |||||||||||||||||||
The accompanying notes are an integral part of these interim financial statements.
Statements of Comprehensive Loss
(Unaudited)
| Quarters Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Net loss | $ | (1,574,174) | $ | (958,562) | |||||||
| Other comprehensive income: | |||||||||||
| Unrealized gain on available-for-sale securities | 65,874 | — | |||||||||
| Comprehensive loss | (1,508,300) | (958,562) | |||||||||
2
NeuroMetrix, Inc.
Statements of Changes in Stockholders' Equity
(Unaudited)
| Series B Convertible Preferred Stock | Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Income | Accumulated Deficit | Total | ||||||||||||||||||||||||||||||||||||||||||
| Number of Shares | Amount | Number of Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2022 | 200 | 1 | 7,675,682 | $ | 777 | $ | 226,934,775 | $ | — | $ | (203,579,866) | $ | 23,355,687 | ||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | 165,361 | — | — | 165,361 | |||||||||||||||||||||||||||||||||||||||
| Vesting of restricted stock under option plan | — | — | 19,512 | 1 | (1) | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Unrealized gain on available-for-sale securities | — | — | — | — | — | 65,874 | 65,874 | ||||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | (1,574,174) | (1,574,174) | |||||||||||||||||||||||||||||||||||||||
| Balance at March 31, 2023 | 200 | $ | 1 | 7,695,194 | $ | 778 | $ | 227,100,135 | $ | 65,874 | $ | (205,154,040) | $ | 22,012,748 | |||||||||||||||||||||||||||||||||
| Series B Convertible Preferred Stock | Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Income | Accumulated Deficit | Total | ||||||||||||||||||||||||||||||||||||||||||
| Number of Shares | Amount | Number of Shares | Amount | ||||||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2021 | 200 | $ | 1 | 6,650,480 | $ | 668 | $ | 222,378,374 | $ | — | $ | (199,163,257) | $ | 23,215,786 | |||||||||||||||||||||||||||||||||
| Stock-based compensation expense | — | — | — | — | 37,632 | — | — | 37,632 | |||||||||||||||||||||||||||||||||||||||
| Issuance of common stock under at the market offering | — | — | 292,500 | 29 | 1,943,023 | — | — | 1,943,052 | |||||||||||||||||||||||||||||||||||||||
| Vesting of restricted stock under option plan | — | — | 1,759 | 3 | (3) | — | — | — | |||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | (958,562) | (958,562) | |||||||||||||||||||||||||||||||||||||||
| Balance at March 31, 2022 | 200 | $ | 1 | 6,944,739 | $ | 700 | $ | 224,359,026 | $ | — | $ | (200,121,819) | $ | 24,237,908 | |||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these interim financial statements.
3
NeuroMetrix, Inc.
Statements of Cash Flows
(Unaudited)
| Three Months Ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net loss | $ | (1,574,174) | $ | (958,562) | |||||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
| Depreciation | 10,222 | 12,877 | |||||||||
| Stock-based compensation | 165,361 | 37,632 | |||||||||
| Inventory reserve charged to cost of revenue | 63,420 | — | |||||||||
| Amortization of premiums and discounts on held-to-maturity securities | (109,198) | — | |||||||||
| Loss on disposal of fixed assets | — | 6,875 | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable | 70,490 | (372,501) | |||||||||
| Inventories | (196,548) | (5,383) | |||||||||
| Prepaid expenses and other current and long-term assets | 78,467 | 37,009 | |||||||||
| Accounts payable | 32,217 | 76,819 | |||||||||
| Accrued expenses and compensation | 338,326 | 424,853 | |||||||||
| Net cash used in operating activities | (1,121,417) | (740,381) | |||||||||
| Cash flows from investing activities: | |||||||||||
| Purchases of available-for-sale securities | (9,336,984) | — | |||||||||
| Proceeds from maturities of held-to-maturity securities | 8,500,000 | — | |||||||||
| Purchases of fixed assets | — | (5,395) | |||||||||
| Net cash used in investing activities | (836,984) | (5,395) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Net proceeds from issuance of stock | — | 1,943,052 | |||||||||
| Net cash provided by financing activities | — | 1,943,052 | |||||||||
| Net increase (decrease) in cash and cash equivalents | (1,958,401) | 1,197,276 | |||||||||
| Cash and cash equivalents, beginning of period | 4,335,020 | 22,572,104 | |||||||||
| Cash and cash equivalents, end of period | $ | 2,376,619 | $ | 23,769,380 | |||||||
The accompanying notes are an integral part of these interim financial statements.
4
NeuroMetrix, Inc.
Notes to Unaudited Financial Statements
For the Three Months Ended March 31, 2023
1.Business and Basis of Presentation
NeuroMetrix, Inc. (the "Company" or "NeuroMetrix") develops and commercializes health care products that utilize non-invasive neurostimulation. Revenues are derived from the sale of medical devices and after-market consumable products and accessories. The Company’s products are sold in the United States and select overseas markets. They are cleared by the U.S. Food and Drug Administration ("FDA") and regulators in foreign jurisdictions where appropriate. The Company has two primary products. DPNCheck® is a point-of-care test for diabetic peripheral neuropathy, which is the most common long-term complication of Type 2 diabetes. Quell is an app-enabled, wearable device for lower extremity chronic pain and for the symptoms of fibromyalgia.
The Company held cash, cash equivalents and investment grade securities totaling $20.3 million on March 31, 2023. The Company believes that its present balance of cash resources and securities coupled with cash inflows from product sales will enable the Company to fund its operations for at least the next twelve months from the date of issuance of the financial statements. Actual cash requirements could differ from management's projections for many reasons, including changes the Company may make to its business strategy, commercial challenges, regulatory developments, changes to research and development programs, supply chain issues, staffing challenges and other items affecting the Company's projected uses of cash.
Unaudited Interim Financial Statements
The accompanying unaudited balance sheet as of March 31, 2023, unaudited statements of operations, statements of comprehensive loss, changes in stockholders' equity and cash flows for the quarters ended March 31, 2023 and 2022 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2022 has been derived from the audited balance sheet as of December 31, 2022 included in the Company's Form 10-K referenced below and does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on March 22, 2023 (File No. 001-33351).
Prior period reclassifications
We have reclassified certain amounts in prior periods to conform with current presentation. During the current period we have reported money market funds within cash and cash equivalents. Money market funds in the amount of $81,751 which were reported within held-to-maturity securities at December 31, 2022 have been reclassified into cash and cash equivalents.
Revenues
Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized at the point in time when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. The Company typically has a single product delivery performance obligation. Accrued product returns using the most likely amount method are estimated based on historical data and evaluation of current information and variable consideration is not constrained.
Accounts receivable are recorded at the amount the Company expects to collect, net of the allowance for doubtful accounts receivable. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses based on customer past payment history, product usage activity, recent customer communications and, if appropriate, assessment of the future credit losses for receivables with similar characteristics. Individual customer balances which are over 60 days past
5
due are reviewed individually for collectability. The Company does not have any off-balance sheet credit exposure related to its customers. Allowance for doubtful accounts was $25,000 as of March 31, 2023 and December 31, 2022.
Two customers accounted for 39% and 43% of total revenues in the quarters ended March 31, 2023 and 2022, respectively. Two customers accounted for 60% and three customers accounted for 55% of accounts receivable as of March 31, 2023 and December 31, 2022, respectively.
Cash and Cash Equivalents
Cash and cash equivalents include bank demand deposits and money market funds that invest primarily in U.S. government securities.
Securities
The Company invests in highly liquid, marketable debt securities with high credit ratings and typically with maturities of two years or less. Individual securities are designated by the Company as either “held-to-maturity" (HTM) or “available-for-sale” (AFS) at the point of investment. Securities classified as short-term have maturities of less than one year. As of March 31, 2023, all marketable securities held by the Company had remaining contractual maturities of one year or less.
HTM securities are valued on an amortized cost basis and reviewed to determine if an allowance for credit losses should be recorded in the statements of operations. AFS securities are valued at fair value. Unrealized gains and losses on AFS securities are included as a component of accumulated other comprehensive income in the balance sheets and statements of stockholders’ equity and a component of total comprehensive loss in the statements of comprehensive income loss. An AFS security is impaired if its fair value is less than amortized cost. Unrealized losses are evaluated to determine if the impairment is credit-related or non credit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and a non credit-related impairment is recognized in other comprehensive income (loss). For certain types of securities, such as U.S. Treasuries, the Company generally expects zero credit losses. No allowance for credit losses was recorded on its securities portfolio as of March 31, 2023
Fair Value
The Company follows the provisions of Financial Accounting Standards Board (the "FASB") Accounting Standards Codification ("ASC") Topic 820-10, Fair Value Measurements and Disclosures ("ASC 820-10"), which defines fair value, establishes a framework for measuring fair value in GAAP and requires certain disclosures about fair value measurements. Fair Value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability.
As a basis for considering such assumptions, ASC 820-10 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: Level 1 observable inputs such as quoted prices in active markets; Level 2 inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and Level 3 unobservable inputs for which there are little or no market data, which require the Company to develop its own assumptions. The hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value (See Note 5).
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.
Recent Accounting Pronouncements
Accounting Standards Updates (ASUs) issued by the FASB are evaluated for their applicability. ASUs not included in the disclosures in this report were assessed and determined to be either not applicable or not expected to have a material impact on our financial statements.
6
Recently adopted accounting pronouncement
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments. The guidance in Accounting Standards Update (“ASU”) 2016-13 replaces the incurred loss impairment methodology under current GAAP. The new impairment requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. It applies to all entities. For trade receivables, loans and held-to-maturity (HTM) debt securities, entities are required to estimate lifetime expected credit losses. Trading and available-for-sale (AFS) debt securities are required to be recorded at fair value. SEC small reporting companies were required to adopt this new guidance in fiscal years beginning on or after December 15, 2022. The Company adopted this guidance on a prospective basis as of January 1, 2023.
2. Comprehensive Income (Loss)
For the quarter ended March 31, 2023, the Company had comprehensive income of $65,874 for unrealized gains on available-for-sale marketable securities, in addition to net loss of $1,574,174 in the statement of operations. There were no components of comprehensive income (loss) in the quarter ended March 31, 2022 other than net loss itself.
3. Net Loss Per Common Share
Basic and dilutive net loss per common share were as follows:
| Quarters Ended March 31, | |||||||||||||||||||||||||||||||||||
| 2023 | 2022 | ||||||||||||||||||||||||||||||||||
| Net loss applicable to common stockholders | $ | (1,574,174) | $ | (958,562) | |||||||||||||||||||||||||||||||
| Weighted average number of common shares outstanding, basic | 7,689,226 | 6,879,348 | |||||||||||||||||||||||||||||||||
| Weighted average number of common shares outstanding, dilutive | 7,689,226 | 6,879,348 | |||||||||||||||||||||||||||||||||
| Net loss per common share applicable to common stockholders, basic and diluted | $ | (0.20) | $ | (0.14) | |||||||||||||||||||||||||||||||
Shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented:
| Quarters Ended March 31, | |||||||||||||||||||||||
| 2023 | 2022 | ||||||||||||||||||||||
| Options | 525,462 | 510,256 | |||||||||||||||||||||
| Unvested restricted stock awards | 85,962 | 47,500 | |||||||||||||||||||||
| Unvested restricted stock units | 179,812 | — | |||||||||||||||||||||
| Convertible preferred stock | 62 | 62 | |||||||||||||||||||||
| Total | 791,298 | 557,818 | |||||||||||||||||||||
4. Securities
The Company's marketable debt securities are classified as either held-to-maturity (HTM) or available-for-sale (AFS) pursuant to ASC 320 - Investments - Debt Securities. HTM securities are valued at amortized cost. The following tables summarize the valuations of HTM securities as of March 31, 2023 and December 31, 2022.
7
8
| March 31, 2023 | |||||||||||||||||
| Held-to-maturity securities | Amortized Cost | Credit Losses | Estimated Fair Value | ||||||||||||||
| U.S. government bonds | $ | 1,484,977 | $ | — | $ | 1,484,625 | |||||||||||
| Corporate bonds | 4,026,570 | — | 3,894,100 | ||||||||||||||
| Commercial paper | 2,962,358 | — | 2,958,894 | ||||||||||||||
| Total | $ | 8,473,905 | $ | — | $ | 8,337,619 | |||||||||||
| December 31, 2022 | |||||||||||||||||
| Held-to-maturity securities | Amortized Cost | Credit Losses | Estimated Fair Value | ||||||||||||||
| U.S. government bonds | $ | 3,457,651 | $ | — | $ | 3,456,580 | |||||||||||
| Corporate bonds | 4,011,569 | — | 3,950,380 | ||||||||||||||
| Commercial paper | 9,395,487 | — | 9,387,914 | ||||||||||||||
| Total | $ | 16,864,707 | $ | — | $ | 16,794,874 | |||||||||||
The following table summarizes the valuations and unrealized gains and losses of AFS securities which are recorded at estimated fair value as of March 31, 2023. The Company held no AFS securities as of December 31, 2022.
| March 31, 2023 | |||||||||||||||||||||||||||||
| Gross Unrealized | |||||||||||||||||||||||||||||
| Available-for-sale securities | Amortized Cost | Gains | Losses | Credit Losses | Estimated Fair Value | ||||||||||||||||||||||||
| U.S. government bonds | $ | 5,953,685 | $ | 36,576 | $ | — | $ | — | $ | 5,990,260 | |||||||||||||||||||
| Corporate bonds | — | — | — | — | — | ||||||||||||||||||||||||
| Commercial paper | 3,383,300 | 29,298 | — | — | 3,412,598 | ||||||||||||||||||||||||
| Total | $ | 9,336,985 | $ | 65,874 | $ | — | $ | — | $ | 9,402,858 | |||||||||||||||||||
The Company evaluates all HTM and AFS securities for impairment at each reporting period. It determined that changes in the fair value of its securities at March 31, 2023 resulted primarily from interest rate fluctuations subsequent to the purchase date of the securities. There was no deterioration in the credit worthiness of the issuers and no credit losses were recorded as of March 31, 2023.
5. Fair Value Measurements
The following tables set forth the Company’s financial instruments that were measured at fair value:
| March 31, 2023 | |||||||||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||
| Assets: | |||||||||||||||||||||||
| Money market funds | $ | 1,667,697 | $ | 1,667,697 | $ | — | $ | — | |||||||||||||||
| U.S. government bonds | 5,990,260 | 5,990,260 | — | — | |||||||||||||||||||
| Commercial paper | 3,412,598 | — | 3,412,598 | — | |||||||||||||||||||
| Total | $ | 11,070,555 | $ | 7,657,957 | $ | 3,412,598 | $ | — | |||||||||||||||
9
| December 31, 2022 | |||||||||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||
| Assets: | |||||||||||||||||||||||
| Money market funds | $ | 1,551,027 | $ | 1,551,027 | $ | — | $ | — | |||||||||||||||
| Total | $ | 1,551,027 | $ | 1,551,027 | $ | — | $ | — | |||||||||||||||
The Company's accounts receivable, accounts payable, and accrued expenses are valued at cost which approximates fair value.
6. Inventories
Inventories consist of the following:
| March 31, 2023 | December 31, 2022 | ||||||||||
| Purchased components | $ | 1,119,662 | $ | 982,129 | |||||||
| Finished goods | 628,453 | 632,858 | |||||||||
| $ | 1,748,115 | $ | 1,614,987 | ||||||||
The Company recorded a charge of $63,420 in the first quarter of 2023 to reduce the carrying value of inventory to net realizable value.
7. Accrued Expenses and Compensation
Accrued expenses and compensation consist of the following:
| March 31, 2023 | December 31, 2022 | ||||||||||
| Professional services | $ | 212,000 | $ | 155,000 | |||||||
| Compensation | 361,115 | 249,224 | |||||||||
| Clinical | 40,000 | — | |||||||||
| Warranty | 15,100 | 16,700 | |||||||||
| Sales Tax | $ | 132,045 | $ | 131,621 | |||||||
| Other | 108,005 | 37,394 | |||||||||
| $ | 868,265 | $ | 589,939 | ||||||||
10
8. Operating Leases
The Company's lease on its Woburn, Massachusetts corporate office and manufacturing facilities (the "Woburn Lease") extends through September 2025 at a monthly base rent of $13,846 and with a 5-year extension option. The Company's lease on its former corporate office in Waltham, Massachusetts (the "Waltham Lease") expired in February 2022. In the first quarter of 2022, a $60,000 reduction in rent expense was recorded upon return of the facility to the lessor. The letter of credit issued by a bank in favor of the Waltham facility was released. For the quarter ended March 31, 2022, the Company recorded sublet income on the Waltham Lease totaling $22,795 within operating expenses on the Company's Statement of Operations.
The following is a maturity analysis of the annual cash flows of the operating lease liabilities as of March 31, 2023:
| 2023 | 124,339 | |||||||
| 2024 | 165,785 | |||||||
| 2025 | 117,431 | |||||||
| Total minimum lease payments | $ | 407,555 | ||||||
| Discount rate, 15% | $ | 78,819 | ||||||
| Lease obligation, current portion | 148,391 | |||||||
| Lease obligation, net of current portion | 180,345 | |||||||
| $ | 407,555 | |||||||
Total recorded rent expense was $49,232 and $24,754, for the quarters ended March 31, 2023 and 2022, respectively. The Company records rent expense on its facility leases on a straight-line basis over the lease term. The remaining operating lease term was 2.5 years as of March 31, 2023.
9. Stockholders’ Equity
Preferred stock and convertible preferred stock consist of the following:
| March 31, 2023 | December 31, 2022 | ||||||||||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized at March 31, 2023 and December 31, 2022; no shares issued and outstanding at March 31, 2023 and December 31, 2022 | $ | — | $ | — | |||||||
| Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at March 31, 2023 and December 31, 2022; 200 shares issued and outstanding at March 31, 2023 and December 31, 2022 | $ | 1 | $ | 1 | |||||||
2023 equity activity
As of March 31, 2023, the Company has 85,962 restricted stock awards and 179,812 restricted stock units that remain unvested. At December 31, 2022 the Company had 96,250 restricted stock awards and 194,731 restricted stock units that were unvested.
2022 equity activity
In January 2022, the Company issued 292,500 shares of common stock under its ATM program with net proceeds of $1,943,052 and issued 20,000 restricted stock awards under its 2004 Stock Option Plan with a value of $104,200.
As of March 31, 2022, the Company has issued 47,500 restricted stock awards that remain unvested. At December 31, 2021 the Company had 30,000 restricted stock awards that were unvested.
11
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements and the accompanying notes to those financial statements included elsewhere in this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. For a description of factors that may cause our actual results to differ materially from those anticipated in these forward-looking statements, please refer to the below section of this Quarterly Report on Form 10-Q titled “Cautionary Note Regarding Forward-Looking Statements.” Unless the context otherwise requires, all references to “we”, “us”, the “Company”, or “NeuroMetrix” in this Quarterly Report on Form 10-Q refer to NeuroMetrix, Inc.
Business Overview
NeuroMetrix is a commercial stage neurotechnology company based in Woburn, Massachusetts. The Company’s mission is to improve individual and population health through innovative medical devices and technology solutions for neurological disorders and pain syndromes. Our core expertise in biomedical engineering has been refined over two decades of designing, building and marketing medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. We are fully integrated with in-house capabilities spanning research and development, regulatory affairs and compliance, sales and marketing, customer support, manufacturing, and product fulfillment. We hold extensive, proprietary intellectual property.
NeuroMetrix created the market for point-of-care nerve testing and introduced sophisticated wearable technology for chronic pain syndromes. Nearly five million patients have been served with our products. Revenue is derived from the sale of medical devices and after-market consumable products and accessories in the United States and select overseas markets. Products are authorized by the U.S. Food and Drug Administration (FDA) and regulators in foreign jurisdictions where appropriate. We have two principal product categories:
–Diagnostic technology - point-of-care peripheral neuropathy assessment
–Therapeutic technology – wearable neuromodulation for chronic pain syndromes
Peripheral neuropathies are diseases of the peripheral nerves. They affect about 10% of adults in the United States, with the prevalence rising to over 30% among individuals 65 years and older. Peripheral neuropathies are associated with loss of sensation, pain, increased risk of falling, weakness, and other complications. People with peripheral neuropathies have a diminished quality of life, poor overall health and higher mortality. The most common specific cause of peripheral neuropathies, accounting for about one-third of cases, is diabetes. The most common long-term complication of diabetes, affecting over 50% of the diabetic population, is diabetic peripheral neuropathy (DPN). Early detection of peripheral neuropathies, such as DPN, is important because there are no treatment options once the nerves have degenerated. Today’s diagnostic methods for peripheral neuropathies range from a simple monofilament test for lack of sensory perception in the feet to a nerve conduction study performed by a specialist. Our DPNCheck nerve conduction technology provides a rapid, low cost, quantitative test for peripheral neuropathies, including DPN. It addresses an important medical need and is particularly effective in screening large populations. DPNCheck has been validated in multiple clinical studies.
Chronic pain is a significant public health problem. It is defined by the National Institutes of Health (NIH) as pain lasting more than 12 weeks. This contrasts with acute pain which is a normal bodily response to injury or trauma. Chronic pain conditions include low back pain, arthritis, fibromyalgia, neuropathic pain, cancer pain and many others. Chronic pain may be triggered by an injury or there may be an ongoing cause such as disease or illness. There may also be no clear cause. Chronic pain can also lead to other health problems. These can include fatigue, sleep disturbance and mood changes, which cause difficulty in carrying out important activities and contributing to disability and despair. In general, chronic pain cannot be cured. Treatment of chronic pain is focused on reducing pain and improving function. The goal is effective pain management.
Chronic pain affects nearly 100 million adults in the United States. The most common approach to chronic pain management is pain medication. This includes over-the-counter (OTC) internal and external analgesics as well as prescription pain medications, both non-opioid and opioid. The approach to treatment is individualized, drug combinations may be employed, and the results are often inadequate. Side effects, including the potential for addiction, are substantial. Nerve stimulation is a long-established category of treatment for chronic pain. This treatment approach is available through implantable devices which have both surgical and ongoing risks. Non-invasive approaches involving transcutaneous electrical nerve stimulation (TENS) have achieved limited efficacy in practice due to power limitations, inadequate dosing and low
12
patient adherence. We believe that our Quell wearable technology for chronic pain is designed to address many of these limitations.
Business Strategy
Our DPNCheck diagnostic technology for peripheral neuropathies has been validated in multiple clinical studies. It contributes attractive gross margins and has posted an average annual growth rate of 16.5% over the past five years. During 2022 we expanded our commercial team for the domestic Medicare Advantage (MA) and launched our next-generation DPNCheck device which enhances the user experience, improves testing efficiency and continues to deliver quantitative results with high sensitivity and specificity. Our 2023 efforts will focus on expanding our MA pipeline, encouraging transition to the new device, and on software development both to connect user testing at the clinic level to the overall business enterprise via a DPNCheck data cloud and to facilitating linkages between clinic testing and patient electronic medical records (EMR). The software projects are complex and costly; however, we see them as essential to expanding usage of DPNCheck, particularly in large organizations.
The MA market has grown rapidly and is expected to soon exceed traditional Medicare fee-for-service in terms of population enrollment. The Centers for Medicare and Medicaid Services (CMS) announced policy changes in Q1 2023 regarding their approach to compliance audits of MA health plans and also regarding coding of patient risk adjustment factors. CMS announced that the audit changes would be immediate and enforced retroactively, and that risk factor coding would be phased-in over three years. The changes to risk factor coding would significantly reduce CMS payments for population screening, including neuropathy. CMS policy changes have created significant uncertainty in the MA market and are likely to be challenged. The ultimate outcome cannot be determined at this time. At present, the Company is working to adapt its commercial strategy to the evolving landscape.
Quell, our wearable neuromodulation technology for chronic pain has been refined over the past seven years with over 200,000 chronic pain patients and is protected by over 20 U.S. utility patents. Patients control and personalize the technology via a mobile phone app, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud. The degree of technological sophistication, combined with our extensive consumer experience and the compelling results of clinical studies has given us the opportunity to redirect this technology away from the commodity-oriented OTC market and into an emerging portfolio of specialized, disease indicated, prescription (Rx) wearable neurotherapeutics.
In 2021 Quell received FDA Breakthrough Device Designation for a fibromyalgia indication. A pivotal double-blind, randomized, sham-controlled clinical study of Quell - fibromyalgia was completed. In 2022 an FDA De Novo marketing authorization was received with an indication for use as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. A limited strategic launch of Quell – fibromyalgia was initiated in late 2022 to confirm the commercial proposition, better understand market dynamics, and refine the fulfillment process prior to full launch in H2 2023.
Quell also received FDA Breakthrough Device Designation in early 2022 for the treatment of chronic Chemotherapy Induced Peripheral Neuropathy (CIPN). A CIPN double-blind, randomized, sham-controlled clinical study employing Quell and funded by the National Cancer Institute (NCI) and the National Institute of Health (NIH) recently completed enrollment. Study results are expected in Q2 2023. A positive outcome would support an FDA DeNovo filing similar to Quell – fibromyalgia and potentially an early 2024 launch of our second Quell Rx portfolio product. We see opportunities with other specific disease indications involving chronic pain, including Chronic Low Back Pain, Post-Acute Sequelae of COVID 19, Chronic Overlapping Pain Conditions (COPC), and Restless Leg Syndrome (RLS).
ADVANCE is our legacy, point-of-care neurodiagnostic technology used primarily for the diagnosis and screening for carpal tunnel syndrome (CTS). While ADVANCE devices are no longer sold, we continue to provide consumables and repair services to our customer base of hand surgeons and manufacturers for use in industrial health.
13
Results of Operations
Comparison of Quarters Ended March 31, 2023 and March 31, 2022
| Three months ended March 31, | Increase (Decrease) | ||||||||||||||||||||||
| 2023 | 2022 | Amount | Percent | ||||||||||||||||||||
| Revenues | $ | 1,724,771 | $ | 2,302,391 | $ | (577,620) | (25.1) | % | |||||||||||||||
| Gross profit | 1,198,399 | 1,793,517 | $ | (595,118) | (33.2) | % | |||||||||||||||||
–% of revenues | 69.5 | % | 77.9 | % | (8.4) | % | |||||||||||||||||
| Operating expenses | 2,908,468 | 2,755,507 | $ | 152,961 | 5.6 | % | |||||||||||||||||
| Other income, net | 135,895 | 3,428 | $ | 132,467 | 3,864.3 | % | |||||||||||||||||
| Net loss | $ | (1,574,174) | $ | (958,562) | $ | 615,612 | 64.2 | % | |||||||||||||||
| Net loss per common share | $ | (0.20) | $ | (0.14) | $ | 0.06 | 42.9 | % | |||||||||||||||
Revenues
Revenues for the first quarter of 2023 decreased by $578 thousand or 25.1% from the first quarter of 2022. DPNCheck sales, primarily focused on Medicare Advantage, accounted for the majority of revenues in both quarters and were the primary contributor to the revenue decline in the first quarter of 2023. DPNCheck® sales declined due to a suspension of patient screening programs, including DPNCheck, by the Company's largest Medicare Advantage customer. This drop was partially offset by increased sales to other Medicare Advantage accounts and the acquisition of new customers.
The Medicare Advantage market is experiencing substantial uncertainty following policy changes recently announced by the Centers for Medicare and Medicaid (CMS) concerning its audit practices and its revisions to patient risk adjustment coding. These changes are extensive and resulted in downward pressure on DPNCheck revenues, although it is too early to determine the duration and magnitude of the impact. Sales of Quell® over the counter and ADVANCE® consumables also decreased as these product lines are being phased out.
Gross Profit
Gross profit for the first quarter of 2023 decreased by $595 thousand or 33.2% from the first quarter of 2022. Gross profit reflected a 69.5% gross margin rate in comparison with 77.9% in the prior year quarter. The decline in revenue, particularly DPNCheck revenue, was the largest contributor to the reduction in gross profit. Gross profit in the first quarter of 2023 was also adversely impacted by charges to adjust inventory to net realizable value and cost increases for electronic components.
Operating Expenses
Operating expenses increased in the first quarter of 2023 by $153 thousand or 5.6% from the first quarter of 2022. The primary contributor across all operating expense categories was increased personnel costs reflecting increased headcount and compensation rates. Promotional spending was reduced in sales and marketing with the discontinuation of Quell OTC sales. Non-cash equity compensation and professional service fees were the major contributors to increased general and administration costs.
Net loss
The net loss in 2023 increased by $616 thousand from 2022. Similarly, net loss per common share increased to ($0.20) per common share in the first quarter of 2023 from ($0.14) per common share in the first quarter of 2022.
14
Liquidity and Capital Resources
The following table contains certain key performance indicators:
| March 31, | December 31, | ||||||||||||||||||||||||||||
| 2023 | 2022 | 2022 | |||||||||||||||||||||||||||
| Cash and cash equivalents | $ | 2,376,619 | $ | 23,769,380 | $ | 4,335,020 | |||||||||||||||||||||||
| Securities | $ | 17,876,763 | $ | — | $ | 16,864,707 | |||||||||||||||||||||||
| Working capital | $ | 21,669,214 | $ | 23,859,997 | $ | 23,000,575 | |||||||||||||||||||||||
| Current ratio | 16.3 | 14.8 | 21.8 | ||||||||||||||||||||||||||
| Net debt position | $ | (18,656,082) | $ | (21,758,917) | $ | (19,885,799) | |||||||||||||||||||||||
| Days sales outstanding | 31.9 | 19.4 | 20.9 | ||||||||||||||||||||||||||
| Inventory turnover | 1.3 | 2.9 | 1.8 | ||||||||||||||||||||||||||
Our primary sources of liquidity are cash and cash equivalents, securities, revenues from the sales of our products, and net proceeds from equity sales. Our expected cash outlays relate to funding operations. We believe that our resources are sufficient to fund our cash requirements over at least the next twelve months from the date of issuance of the financial statements.
As of March 31, 2023, we had $20.3 million in cash and cash equivalents and securities, working capital of $21.7 million, and a current ratio of 16.3. We had no term debt or borrowings. Net debt, defined as short and long-term debts, less cash, cash equivalents and securities, continues to be negative.
Days sales outstanding (DSO) reflect our customer payment terms which vary from payment on order to 60 days from shipment date. DSO of 31.9 at March 31, 2023 versus 19.4 at March 31, 2022 primarily reflects a deterioration of the accounts receivable aging and the modest effect of a shift in the Company’s product line composition of revenue to DPNCheck sales with 30-60 day credit terms and away from Quell OTC sales with immediate credit card payment. Inventory turnover rate declined during the quarter ended March 31, 2023 due to the combined effects of inventory growth and the drop in sales.
Cash Flows
| Three months ended March 31, | |||||||||||||||||
| 2023 | 2022 | Change | |||||||||||||||
| Net cash provided by (used in): | |||||||||||||||||
–Operating activities | $ | (1,121,417) | $ | (740,381) | $ | (381,036) | |||||||||||
–Investing activities | (836,984) | (5,395) | (831,589) | ||||||||||||||
–Financing activities | — | 1,943,052 | (1,943,052) | ||||||||||||||
| Net change in cash and cash equivalents | $ | (1,958,401) | $ | 1,197,276 | |||||||||||||
Operating activities
Operations cash usage in the first quarter of 2023 increased by $381 thousand from the prior year quarter reflecting an increase in net loss of $616 thousand offset by the net change in the components of working capital which included an increase in inventory $191 thousand and a reduction of accounts receivable $443 thousand.
15
Investing activities
Investing activities in the first quarter of 2023 reflect $9.3 million in purchases of available-for-sale (AFS) securities and $8.5 million in maturities of held-to-maturity (HTM) securities.
Financing activities
There were no financing activities for the first quarter of 2023. During the first quarter of 2022, $1.9 million was raised through the ATM facility.
We continue to maintain an effective shelf registration statement covering the sales of shares of our common stock and other securities, giving us the opportunity to raise funding when needed or otherwise considered appropriate at prices and on terms to be determined at the time of any such offerings. Pursuant to the instructions to Form S-3, we have the ability to sell shares under the shelf registration statement, during any 12-month period, in an amount less than or equal to one-third of the aggregate market value of our common stock held by non-affiliates. If we raise additional funds by issuing equity or debt securities, either through the sale of securities pursuant to a registration statement or by other means, our existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders.
16
Cautionary Note Regarding Forward-Looking Statements
The statements contained in this Quarterly Report on Form 10-Q, including under the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other sections of this Quarterly Report, include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including, without limitation, statements regarding our or our management’s expectations, hopes, beliefs, intentions or strategies regarding the future, such as our estimates regarding anticipated operating losses, future revenues and projected expenses, the effect of the COVID-19 pandemic on our operating capabilities, our future liquidity and our expectations regarding our needs for and ability to raise additional capital; our ability to manage our expenses effectively and raise the funds needed to continue our business; our belief that there are unmet needs for the management of chronic pain and in the diagnosis and treatment of diabetic neuropathy; our expectations surrounding our commercialized neurostimulation and neuropathy diagnostic products; our expected timing and our plans to develop and commercialize our products; our ability to meet our proposed timelines for the commercial availability of our products; our ability to obtain and maintain regulatory approval of our existing products and any future products we may develop; regulatory and legislative developments in the United States and foreign countries; the performance of our third-party manufacturers; our ability to obtain and maintain intellectual property protection for our products; the successful development of our sales and marketing capabilities; the size and growth of the potential markets for our products and our ability to serve those markets; our estimate of our customer returns of our products; the rate and degree of market acceptance of any future products; our reliance on key scientific management or personnel; the payment and reimbursement methods used by private or government third party payers; and other factors discussed elsewhere in this Quarterly Report on Form 10-Q. The words “believe,” “may,” “will,” “estimate,” ��continue,” “anticipate,” “intend,” “expect,” “plan” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this quarterly report are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the section titled “Risk Factors” in our Annual Report on Form 10-K. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We do not use derivative financial instruments in our investment portfolio and have no foreign exchange contracts. Our financial instruments consist of cash and cash equivalents. We consider investments that, when purchased, have a remaining maturity of 90 days or less to be cash equivalents. The primary objectives of our investment strategy are to preserve principal, maintain proper liquidity to meet operating needs, and maximize yields. To minimize our exposure to an adverse shift in interest rates, we invest mainly in cash equivalents and short-term investments with a maturity of twelve months or less and maintain an average maturity of twelve months or less. We do not believe that a notional or hypothetical 10% change in interest rate percentages would have a material impact on the fair value of our investment portfolio or our interest income.
17
Item 4. Controls and Procedures
(a) Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2023, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
(b) Changes in Internal Controls. In connection with our evaluation of the Company’s internal controls over financial reporting during 2022, we identified a control deficiency in inventory accounting which represented a material weakness in our controls over financial reporting as of December 31, 2022. Specifically, our controls were not designed or implemented to ensure the proper review and determination of inventory costing, and the valuation of inventory net realizable value. The Company has taken steps to remediate the material weakness in inventory accounting controls by expanding its period-end closing process to require that the Corporate Controller perform and document a review of inventory costing and also prepare an analysis of inventory net realizable value, which analysis is required to be reviewed and approved by the Chief Financial Officer. This change in internal controls was implemented during the closing process for the first quarter of 2023.
18
PART II – OTHER INFORMATION
Item 1. Legal Proceedings
While we are not currently a party to any material legal proceedings, we could become subject to legal proceedings in the ordinary course of business. We are not aware of and do not expect any such potential issues. However, should they occur, we do not expect them to have a significant impact on our financial position.
Item 1A. Risk Factors
There have been no material changes in the risk factors described in “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.
19
Item 6. Exhibits
| Exhibit No. | Description | |||||||
| Certification of Principal Executive Officer Under Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended, and pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002. Filed herewith. | ||||||||
| Certification of Principal Financial Officer Required Under Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended, and pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith. | ||||||||
| Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350. Furnished herewith. | ||||||||
| 101.INS | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). Filed herewith. | |||||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. Filed herewith. | |||||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. Filed herewith. | |||||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. Filed herewith. | |||||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. Filed herewith. | |||||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. Filed herewith. | |||||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). Filed herewith. | |||||||
20
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| NEUROMETRIX, INC. | ||||||||
| May 3, 2023 | /s/ | SHAI N. GOZANI, M.D., PH. D. | ||||||
| Shai N. Gozani, M.D., Ph. D. | ||||||||
| Chairman, President and Chief Executive Officer | ||||||||
| May 3, 2023 | /s/ | THOMAS T. HIGGINS | ||||||
| Thomas T. Higgins | ||||||||
| Senior Vice President, Chief Financial Officer and Treasurer | ||||||||